These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37437437)

  • 41. Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases.
    Wang Y; Yuan YF; Lin HC; Li BK; Wang FH; Wang ZQ; Ding PR; Chen G; Wu XJ; Lu ZH; Pan ZZ; Wan DS; Sun P; Yan SM; Xu RH; Li YH
    Chin J Cancer; 2017 Oct; 36(1):78. PubMed ID: 28969708
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases.
    Kawamura J; Yazawa T; Sumida K; Kida Y; Ogawa R; Tani M; Kawasoe J; Yamamoto M; Harada H; Yamamoto H; Zaima M
    World J Surg Oncol; 2016 Feb; 14():56. PubMed ID: 26911142
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of Genomic Mutation and Timing of Y90 Radioembolization in Colorectal Liver Metastases.
    Dabrowiecki A; Sankhla T; Shinn K; Bercu ZL; Ermentrout M; Shaib W; Cardona K; Newsome J; Kokabi N
    Cardiovasc Intervent Radiol; 2020 Jul; 43(7):1006-1014. PubMed ID: 32367230
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Liver resection after chemotherapy and tumour downsizing in patients with initially unresectable colorectal cancer liver metastases.
    Devaud N; Kanji ZS; Dhani N; Grant RC; Shoushtari H; Serrano PE; Nanji S; Greig PD; McGilvray I; Moulton CA; Wei A; Gallinger S; Cleary SP
    HPB (Oxford); 2014 May; 16(5):475-80. PubMed ID: 23927606
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial.
    Ychou M; Rivoire M; Thezenas S; Quenet F; Delpero JR; Rebischung C; Letoublon C; Guimbaud R; Francois E; Ducreux M; Desseigne F; Fabre JM; Assenat E
    Ann Surg Oncol; 2013 Dec; 20(13):4289-97. PubMed ID: 23955585
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nomogram for prediction of prognosis in patients with initially unresectable colorectal liver metastases.
    Imai K; Allard MA; Castro Benitez C; Vibert E; Sa Cunha A; Cherqui D; Castaing D; Bismuth H; Baba H; Adam R
    Br J Surg; 2016 Apr; 103(5):590-9. PubMed ID: 26780341
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic impact of additive chemotherapy after curative resection of metachronous colorectal liver metastasis: a single-centre retrospective study.
    Kelm M; Schollbach J; Anger F; Wiegering A; Klein I; Germer CT; Schlegel N; Kunzmann V; Löb S
    BMC Cancer; 2021 May; 21(1):490. PubMed ID: 33941104
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The prognostic value of fluorodeoxyglucose positron emission tomography metabolic tumor volume in solitary colorectal liver metastasis.
    Huang YT; Park J; Chong S; Hugh TJ; Ng WL; Lin M
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e262-e270. PubMed ID: 27451967
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes in serum lactate dehydrogenase levels as markers of pathological response and prognosis in colorectal liver metastases patients receiving neoadjuvant chemotherapy followed by resection.
    Chen J; Chen Q; Yao J; Jiang Y; Zhou J; Zhao H; Cai J
    Ann Palliat Med; 2021 Oct; 10(10):10276-10292. PubMed ID: 34551571
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.
    Ruers T; Van Coevorden F; Punt CJ; Pierie JE; Borel-Rinkes I; Ledermann JA; Poston G; Bechstein W; Lentz MA; Mauer M; Folprecht G; Van Cutsem E; Ducreux M; Nordlinger B; ; ; ;
    J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28376151
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
    Boige V; Malka D; Elias D; Castaing M; De Baere T; Goere D; Dromain C; Pocard M; Ducreux M
    Ann Surg Oncol; 2008 Jan; 15(1):219-26. PubMed ID: 17896145
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy.
    Sakamoto Y; Miyamoto Y; Beppu T; Nitta H; Imai K; Hayashi H; Baba Y; Yoshida N; Chikamoto A; Baba H
    Anticancer Res; 2015 Apr; 35(4):2359-68. PubMed ID: 25862901
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    Cremolini C; Casagrande M; Loupakis F; Aprile G; Bergamo F; Masi G; Moretto R R; Pietrantonio F; Marmorino F; Zucchelli G; Tomasello G; Tonini G; Allegrini G; Granetto C; Ferrari L; Urbani L; Cillo U; Pilati P; Sensi E; Pellegrinelli A; Milione M; Fontanini G; Falcone A
    Eur J Cancer; 2017 Mar; 73():74-84. PubMed ID: 27986363
    [TBL] [Abstract][Full Text] [Related]  

  • 54. FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases.
    Beppu T; Hayashi N; Masuda T; Komori H; Horino K; Hayashi H; Okabe H; Baba Y; Kinoshita K; Akira C; Watanebe M; Takamori H; Baba H
    Anticancer Res; 2010 Mar; 30(3):1015-20. PubMed ID: 20393029
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case-Control Study.
    Dhir M; Jones HL; Shuai Y; Clifford AK; Perkins S; Steve J; Hogg ME; Choudry MH; Pingpank JF; Holtzman MP; Zeh HJ; Bahary N; Bartlett DL; Zureikat AH
    Ann Surg Oncol; 2017 Jan; 24(1):150-158. PubMed ID: 27431415
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases.
    Link KH; Pillasch J; Formentini A; Sunelaitis E; Leder G; Safi F; Kornmann M; Beger HG
    Eur J Surg Oncol; 1999 Aug; 25(4):381-8. PubMed ID: 10419708
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metabolic tumor volume predicts long-term survival after transplantation for unresectable colorectal liver metastases: 15 years of experience from the SECA study.
    Grut H; Line PD; Syversveen T; Dueland S
    Ann Nucl Med; 2022 Dec; 36(12):1073-1081. PubMed ID: 36241941
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic value of total tumor volume in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy.
    Liang SB; Teng JJ; Hu XF; Yang XL; Luo M; Fang XN; Liu DS; Chen Y; Fu LW
    BMC Cancer; 2017 Jul; 17(1):506. PubMed ID: 28754109
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Conversion therapy for synchronous colorectal liver metastases].
    Morohashi H; Yokoyama H; Akasaka H; Sakamoto Y; Koyama M; Murata A; Hakamada K
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1665-7. PubMed ID: 24393882
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optimizing the selection of technically unresectable colorectal liver metastases.
    Kobayashi K; Inoue Y; Kitano Y; Sato S; Oba A; Ono Y; Sato T; Ito H; Mise Y; Saiura A; Takahashi Y
    Surgery; 2023 Feb; 173(2):442-449. PubMed ID: 36384649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.